» Articles » PMID: 10685800

Accurately Describing Changes in Disease Activity in Systemic Lupus Erythematosus

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2000 Feb 24
PMID 10685800
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.

Methods: In total, 230 patients with SLE followed at the University of Toronto Lupus Clinic who had 5 visits 3 months apart in 1992-93 were studied. At each visit a standard protocol was completed. A clinician who did not know the patients or their SLEDAI scores evaluated each patient record and assigned a clinical activity level. "Flare" was defined by new or increased therapy for active disease, an expression of concern, or use of the term "flare" in the physician's notes. The SLEDAI score was calculated from the database.

Results: SLEDAI scores described a range of clinical activity as recognized by the clinician. Median SLEDAI scores ranged from 2 (inactive disease) to 8 (persistently active or flare). When the clinician assessed the patient to be improved, the median SLEDAI score decreased by 2. When the clinician assessed that the patient was experiencing a flare, the SLEDAI score increased by a median of 4.

Conclusion: Based on our data we propose the following outcomes for patients with SLE: flare, an increase in SLEDAI > 3; improvement is a reduction in SLEDAI of > 3; persistently active disease is change in SLEDAI +/- 3; and remission a SLEDAI of 0. These outcomes will allow a more complete description of a patient's response to therapeutic intervention in a responder index.

Citing Articles

Lupus pregnancy outcomes in women with previous adverse outcomes: a prospective cohort study.

Ravindran V, Bhadran S, Divakaran M, Reshma V Clin Rheumatol. 2024; 43(9):2911-2917.

PMID: 39017917 DOI: 10.1007/s10067-024-07069-1.


Urine biomarker score captures response to induction therapy with lupus nephritis.

Cody E, Wenderfer S, Sullivan K, Kim A, Figg W, Ghumman H Pediatr Nephrol. 2023; 38(8):2679-2688.

PMID: 36715772 PMC: 10393841. DOI: 10.1007/s00467-023-05888-z.


Heterogeneity of Stroke in Patients with Systemic Lupus Erythematosus.

Kitano T, Hirano T, Okazaki S, Itotagawa E, Yagita Y, Morita Y Intern Med. 2022; 61(20):3045-3052.

PMID: 36244734 PMC: 9646340. DOI: 10.2169/internalmedicine.9228-21.


An association study on the risk, glucocorticoids effectiveness, and prognosis of systemic lupus erythematosus: insight from mitochondrial DNA copy number.

Li Z, Zong Q, Zhai C, Yu G, Hu W, Wang Y Immunol Res. 2022; 70(6):850-859.

PMID: 36103009 DOI: 10.1007/s12026-022-09318-4.


Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.

Furie R, Hough D, Gaudy A, Ye Y, Korish S, Delev N Lupus Sci Med. 2022; 9(1).

PMID: 35169036 PMC: 8852715. DOI: 10.1136/lupus-2021-000581.